The Centers for Medicare & Medicaid Services (CMS) has announced the determination of a benefit category and coverage for CGM.
In order to be included in this category, the system must be defined as a “therapeutic” CGM, meaning you can make treatment decisions using the device. The only CGM system that falls within this classification is Dexcom’s G5 CGM System, which received FDA approval for insulin dosing last month.
“This landmark CMS Ruling will make available the most important technology in diabetes management to the Medicare population,” said Kevin Sayer, Dexcom President and Chief Executive Officer. “We are pleased with this important step forward and we look forward to working with Medicare on implementing coverage in the coming months to ensure beneficiaries have access to this life-saving device.”
Medtronic’s CGM has not received FDA approval for dosing and therefore will not be included in this category and will not, at this time, be covered by Medicare.